Schrodinger, Inc. (NASDAQ:SDGR)
| Market Cap | 1.96B+27.1% |
| Revenue (ttm) | 259.04M+8.9% |
| Net Income | -54.34M+70.0% |
| EPS | -0.74+70.2% |
| Shares Out | 74.81M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 634,461.741 |
| Open | 27.76 |
| Previous Close | 27.14 |
| Day's Range | 25.97 - 27.86 |
| 52-Week Range | 10.95 - 33.78 |
| Beta | 1.62 |
| Analysts | Buy |
| Price Target | 19.00(-27.61%) |
| Earnings Date | Nov 4, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About SDGR
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
4 firms rating SDGR in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 4, 2026Earnings report
Ask Barron about SDGR
$SDGR stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SDGR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SDGR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SDGR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
SDGR Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Software products and services | $32.54M | 50.00% |
| Hosted software | $15.15M | 23.28% |
| On-premise software | $9.30M | 14.28% |
| Software maintenance | $4.88M | 7.49% |
| Professional services | $3.22M | 4.95% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New SDGR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SDGR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SDGR
| ETF | Est. Holding Size |
|---|---|
| IJRiShares Core S&P Small-Cap ETF | $93.16M |
| ARKGARK Genomic Revolution ETF | $70.67M |
| VTIVanguard Morningstar Total Stock Market ETF | $61.02M |
| VBVanguard Morningstar Small-Cap ETF | $43.61M |
| IWMiShares Russell 2000 ETF | $39.77M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $24.27M |
Estimated from each fund’s disclosed top holdings × AUM
SDGR Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SDGR’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Biotech: 99 sector peers carry a ranked score; this one has no qualifying buying in the window · sector average 59.5
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 22Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.